DENVER & DUSSELDORF, GERMANY–(BUSINESS WIRE)–Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide
developer and marketer of diagnostic test kits, announced today the launch of
its new Hyaluronic Acid (HA) Immmunoturbidimetric Test Kit for use on automated
chemistry analyzers. The announcement was made in Dusseldorf, Germany,
at MEDICA 2011, the world’s largest medical industry trade fair, where the
product is being exhibited to medical professionals from around the world.
The automated HA test kit marks the first product to be
released under a Joint Product Development Agreement (JPDA) signed in 2010 with
the ELITech Group to co-develop new diagnostic tests. The new
HA test kit will be available worldwide through ELITech; it will be available
in the U.S.
for research purposes only through Corgenix.
“The launch of this new HA product reaffirms our market
leadership position in non-invasive biomarkers for assessing chronic liver
disease,” said Corgenix President and CEO Douglass Simpson. “We have a very
active development program with ELITech and over the next few years will be
bringing additional new and exciting products to the global market.”
This is the second Corgenix product for measuring blood
levels of hyaluronic acid. The first product is configured as an ELISA
microplate and has been commercialized worldwide since 1998. It is CE marked
for the European Union to assess the degree of liver fibrosis and cirrhosis in
chronic liver disease. The microplate product has not been cleared or approved
in the U.S.
by the Food and Drug Administration (FDA) and is available for research use
only (not for use in diagnostic procedures).
The Corgenix Hyaluronic Acid Immmunoturbidimetric Test Kit
is expected to be CE-marked for sale in the European Union within a few weeks.
In all countries where the use of this product has not been cleared by local
regulating agencies, the products shall not be used for diagnostic use as the
performance characteristics have not been established. Corgenix Hyaluronic Acid
Immmunoturbidimetric Test Kit is not FDA cleared or approved for diagnostic use
in the U.S.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized
diagnostic kits for immunology disorders, vascular diseases and bone and joint
disorders, including the worlds only non-blood-based test for aspirin effect.
Corgenix diagnostic products are commercialized for use in clinical
laboratories throughout the world. The company currently sells over 50
diagnostic products through a global distribution network. More information is
available at www.corgenix.com.
About the ELITech Group
The ELITech Group is a privately held group of worldwide manufacturers and
distributors of in vitro diagnostic equipment and reagents. By bringing
together IVD specialty companies that offer innovative products and solutions,
ELITech Group has become a major contributor in advancing clinical diagnostics
to laboratories in the proximity market, those operating closer to the patient.
The ELITech Group manufactures and distributes diagnostic products for clinical
chemistry, microbiology, immunology, and molecular biology though direct sales
and a distribution network encompassing more than 100 countries. More
information is available at www.elitechgroup.com.
